drugset / Trial / NCT03448978
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Timeline
- Start
- 2018-03-08
- Primary completion
- 2021-04-19
- Completion
- 2021-06-03
Outcome
Outcome not reported
Stopped (Enrollment): “Phase 1 enrollment completed. Further clinical development terminated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Descartes-08 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |